Banner News

Singapore, February 9, 2023 – Detection of the latest SARS-CoV-2 Variant Strain


In response to the rise of new Covid-19 variants, Credo Diagnostics Biomedical Pte Ltd continues to ensure the effectiveness of our assays using BLASTn analysis. (with the oligonucleotide primers and probes of the assays involving SARS-CoV-2 detection) against the sequences listed in GISAID from September 1st, 2022 to January 31st, 2023.


We are pleased to announce that our VitaPCR™ system is capable of detecting the Omicron XBB.1.5 subvariant, and our analysis has confirmed that the performance of our SARS-CoV-2 RNA detection assays* is not impacted by the Omicron subvariant, XBB.1.5.


*The SARS-CoV-2 RNA detection assays include:
VitaPCR™ Influenza/SARS-CoV-2 (Flu/SC2) Assay (PCRAE0128)
. VitaPCR™ SARS-CoV-2 Assay (PCRAE0114)
VitaPCR™ SARS-CoV-2 Gen 2 Assay (PCRAE0120)


For more information, contact us at


About Credo Diagnostics Biomedical Pte. Ltd.

Credo Diagnostics develops and manufactures innovative, easy-to-use, and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas of Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.


We at Credo Diagnostics pioneer accessible diagnostic platforms to improve the lives of those we love. We believe providing the right information to the right people at the right time leads to better outcomes.